Comparative Pharmacology
Head-to-head clinical analysis: LARIN 1 5 30 versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LARIN 1 5 30 versus SOJOURN.
LARIN 1.5/30 vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses FSH and LH, preventing ovulation; norethindrone induces endometrial changes and increases cervical mucus viscosity, impeding sperm penetration.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
One tablet (norethindrone acetate 1.5 mg, ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
400 mg orally once daily
None Documented
None Documented
Ethinyl estradiol: 13-19 hours; Norethindrone: 7-9 hours. Steady-state achieved in ~5-7 days.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Renal (40% as metabolites, <10% unchanged); fecal (50% as metabolites); biliary (minor).
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive